Mood [affective] disorders Mental and Behavioural Disorders Mood [affective] disorders
Conditions
Interventions
The NHS funded six-year REDUCE (REviewing long term antiDepressant Use by Careful monitoring in Everyday practice) research programme aims to identify feasible, safe, effective, and cost-effective way
analyses of qualitative interviews and focus groups carried out with patients and practitioners respectively on the difficulties of antidepressant cessation in work stream 2
the development of the intervention using ‘think-aloud’ interviews with patients and practitioners in work stream 3
a feasibility randomised trial in work stream 4
the lived experience of our patient and public involvement (PPI) advisors
and our team's research and development expertise.
WS5 is a fully powered randomised controlled trial (RCT), which aims to assess the effectiveness of the Internet and telephone interventions. It wil
Sponsors
University of Southampton
Eligibility
Sex/Gender
All
Age
18 Years to 110 Years
Inclusion criteria
Inclusion criteria: 1. Patients who are taking long-term antidepressant treatment, which is not indicated according to the NICE depression guideline (NICE, 2009): 1.1 Treated for more than 1 year for a first episode, and 1.2 Treated for more than 2 years for a recurrent episode, who are: 1.3 No longer depressed or judged to be at significant risk of relapse 2. Adults over 18 years
Exclusion criteria
Exclusion criteria: 1. At risk for relapse: 1.1 Current significant depressive symptoms on the PHQ-9 (see below) despite antidepressant treatment 1.2 Current significant anxiety symptoms on the GAD-7 1.3 Current suicidal ideas 1.4 Current psychiatric outpatient or inpatient treatment for depression 2. Bipolar disorder, comorbid psychosis, substance use, or dementia as a primary diagnosis 3. Spoken or written English language inadequate to take part in interviews or complete questionnaires 4. Another indication for taking antidepressants, e.g. neuropathic pain
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Depression measured by PHQ-9 score at baseline and 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Depression measured by PHQ-9 score at baseline and 12 months 2. Discontinuation of antidepressants (for at least 2 months) measured at 6 months 3. Mental wellbeing measured using the Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS) at baseline, 6 and 12 months 4. Antidepressant withdrawal symptoms measured using the Discontinuation Emergent Signs and Symptoms Scale (DESS) at baseline, 3 and 6 months 5. Antidepressant side effects measured using the Antidepressant Side-Effects Check-list (ASEC) and Changes in Sexual Functioning Questionnaire (CSFQ-C) at baseline, 6 and 12 months 6. Patient satisfaction measured using a modified version of the 'Medical Interview Satisfaction Scale' (MISS-29) at 6 and 12 months 7. Enablement measured using the Patient Enablement Instrument (PEI) at 6 and 12 months 8. Quality of life measured using the EuroQol-5D-5L and Medical Outcomes Study Short Form SF-12 at baseline, 6 and 12 months 9. Use of services (to calculate costs) using a bespoke questionnaire at baseline, 6 and 12 months | — |
Countries
England, United Kingdom
Outcome results
None listed